What the trials show
In the STEP 1 extension, people who had taken semaglutide regained, on average, about two-thirds of their earlier weight loss in the year after treatment and lifestyle support stopped. This was a selected extension group, and its average does not predict what will happen to every patient.
SURMOUNT-4 used a different design. After an initial period on tirzepatide, participants were randomised to continue or to switch to placebo. The placebo group regained weight on average, while continued treatment kept or extended the loss. Both studies support planning obesity treatment over the longer term.
An average is no forecast for you
A trial average blends many individual results. Some people regain more and some less, and the reasons for stopping vary. Ongoing support, other treatments, changes in health and follow-up all shape what happens in practice. Observational data and randomised withdrawal studies also answer different questions.
Claims that everyone regains all their weight, or that one diet guarantees no regain, go beyond these findings. The evidence supports preparing for regain and keeping an eye on your health. It gives no grounds to blame you in advance or to promise an easy fix.
Why you may need to stop
People stop for many reasons: side effects, pregnancy planning, cost, supply, limited benefit or a change of mind. Some situations need you to stop promptly. Others allow a planned review. Ask your prescriber which applies and whether your glucose treatment or other medicines need adjusting.
Nobody has proven a home-made taper or widely spaced doses prevent regain. If a clinician suggests a tailored approach, ask about the evidence, the exact instructions and the follow-up. Do not stretch out treatment with leftover medicine or an unregulated substitute.
Build a follow-up plan
Before you stop, agree how to monitor appetite, weight and other relevant health measures, when to ask for a review and what support stays available. Keep the plan realistic. Constant weighing or severe restriction makes the change harder and brings new problems.
If you regain weight, a review looks at how much, any symptoms, your eating pattern and treatment options. Going back for a review is no admission of failure. Your health has changed and your care should respond. If restarting comes up, your clinician should choose a suitable regimen based on the length of the gap, how you coped before and your current situation. Your old dose should not be restarted by default.
Be open if you restart
If you have tried to restart with an old supply, tell your clinician the exact doses and dates. They need an accurate history to judge tolerability and plan further treatment.
Do not hide returning appetite or weight gain for fear of blame. These changes are the reason follow-up matters. A good service assesses where you are now and what options exist. It should never make access depend on a picture-perfect account of the time since you stopped.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- STEP 1 extension: Weight regain after semaglutide withdrawal pubmed.ncbi.nlm.nih.gov
- SURMOUNT-4: Continued tirzepatide and weight maintenance jamanetwork.com
- NICE NG246: Overweight and obesity management nice.org.uk
Spotted something out of date? Report a mistake.